For patients with metastatic non–small-cell lung cancer (mNSCLC), the last decade has
been characterized by critical progress that has contributed to substantially improved …

Inhibitory antibodies targeting programmed death protein 1 (PD-1) and programmed death
ligand 1 (PD-L1) have resulted in improved outcomes for many patients with metastatic non …

Immunotherapy for non-small cell lung cancer (NSCLC) is incorporated increasingly in first
line treatments protocols. Multiple phase 3 studies have tested different medications …

Many decades in the making, immunotherapy has demonstrated its ability to produce
durable responses in several cancer types. In the last decade, immunotherapy has shown …

Non-small cell lung cancer (NSCLC) represents the most common and fatal type of primary
lung malignancies. NSCLC is often diagnosed at later stages and requires systemic …

Background: The treatment of non-small-cell lung carcinoma (NSCLC) has changed
markedly in recent years as a result of two major treatment milestones: Targeted therapy and …

In non-small cell lung cancer (NSCLC), the first immune checkpoint inhibitor to be approved
by the US Food and Drug Administration was nivolumab, based on a survival advantage …

Immunotherapy has fundamentally changed the treatment landscape for many patients with
cancer. mAbs targeting programmed cell death-1 (PD-1), programmed cell death ligand-1 …

This review describes trials evaluating the monoclonal antibody pembrolizumab (an
immunotherapy that blocks the interaction between programmed death-1 and programmed …

Emerging evidence on the role of the antitumor activity of the immune system has generated
great interest in immunotherapy even for tumors that were historically considered as …